Permira is a global investment firm that backs successful businesses with growth ambitions. Founded in 1985, the firm advises funds with total committed capital of €77bn and makes long-term majority and minority investments across two core asset classes, private equity and credit.
The Permira private equity funds have made approximately 300 private equity investments in four key sectors: Technology, Consumer, Healthcare and Services.
Permira employs over 470 people in 15 offices across Europe, the United States and Asia.
Ergomed plc is an AIM listed provider of specialist services to the pharmaceutical industry spanning all clinical development phases, post-approval pharmacovigilance, and medical information.
Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance solutions integrated under the PrimeVigilance brand, and a full range of high-quality clinical research and trial management services under the Ergomed brand, with a strong heritage in the development of drugs in rare diseases and oncology.
Bidco is a newly incorporated company controlled and indirectly wholly owned by the Permira Funds, advised by Permira Advisers LLP
On 4 September 2023, the boards of Ergomed and Bidco announced that they had agreed the terms of a recommended cash offer pursuant to which Bidco will acquire the entire issued and to be issued share capital of Ergomed.
Publication of the Scheme Document
The Perivan shareholder communications team was delighted to work with Covington & Burling who acted as legal adviser to Ergomed on the production of the Scheme and associated and ancillary documents, which were successfully published and posted to qualifying shareholders on 22nd September 2023.
For further information, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.